TrueMark Investments LLC Sells 1,002 Shares of Novo Nordisk A/S (NYSE:NVO)

TrueMark Investments LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,156 shares of the company’s stock after selling 1,002 shares during the period. TrueMark Investments LLC’s holdings in Novo Nordisk A/S were worth $1,046,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Massachusetts Financial Services Co. MA grew its holdings in shares of Novo Nordisk A/S by 2.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 79,660 shares of the company’s stock worth $9,485,000 after acquiring an additional 2,166 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Novo Nordisk A/S by 16.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 204,583 shares of the company’s stock worth $24,360,000 after purchasing an additional 28,988 shares during the period. Eagle Asset Management Inc. raised its holdings in Novo Nordisk A/S by 10.4% in the third quarter. Eagle Asset Management Inc. now owns 17,893 shares of the company’s stock worth $2,131,000 after purchasing an additional 1,680 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Finally, Brown Brothers Harriman & Co. grew its position in shares of Novo Nordisk A/S by 4.7% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 37,367 shares of the company’s stock worth $4,449,000 after buying an additional 1,688 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.3 %

Shares of NYSE:NVO opened at $73.57 on Wednesday. Novo Nordisk A/S has a 1 year low of $73.20 and a 1 year high of $148.15. The stock’s fifty day moving average price is $83.01 and its 200-day moving average price is $99.94. The company has a market cap of $330.15 billion, a P/E ratio of 22.36, a PEG ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NVO. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.